NCT07507682Recruiting
Can Astaxanthin Help Manage Asthma in POlluted Areas?
Investigating Astaxanthin as a Novel Therapy for Asthma Management in Polluted Environments
Source: ClinicalTrials.gov · Last updated 2 Apr 2026
Brief summary (registry, in English)
This study will test whether astaxanthin, a naturally occurring antioxidant supplement, can improve lung function, reduce airway inflammation, and improve asthma control in adults with mild-to-moderate asthma. Participants will receive astaxanthin and placebo in random order in a double-blind crossover design. Each treatment period lasts 4 weeks and is separated by a 3-week washout period. The study also measures indoor and personal air pollution exposure to examine whether pollution influences asthma symptoms, airway responsiveness, and response to treatment. Exploratory thoracic bioelectrical impedance spectroscopy will be assessed alongside standard respiratory tests.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- First submitted
- 27 Mar 2026
- Start date
- 15 May 2026
- Primary completion date
- 20 Jul 2026
- Lead sponsor
- Middlesex University
- Diseases
- Asthma
- NCT number
- NCT07507682
What you commit to
- Study type: Interventional
- Planned participants: 25
- From 15 May 2026 to the primary completion date, 20 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participation in another interventional drug or supplement study within the preceding 3 months
Other illness
- Respiratory tract infection within the preceding 4 weeks
- Presence of significant co-morbidities, including CVD or autoimmune or systemic inflammatory diseases
- Renal or gastrointestinal disorders that may affect astaxanthin absorption and metabolism
- Known allergy or hypersensitivity to ASTX or any components of the study supplement
- History of current evidence of alcohol or substance abuse
- Other significant chronic respiratory disease (e.g., COPD, bronchiectasis)
Other
- Current smokers or vapers which is associated with chronic airway remodelling, reduce hyperresponsiveness to bronchodilators, and increased neutrophilic inflammation, which can obscure the true effects of asthma-target interventions
- Pregnant or lactating individuals
- Use of medicines with a narrow therapeutic index where supplement interactions may pose risk (e.g., ciclosporin/tacrolimus, warfarin), assessed by investigator
Who the study is looking for
- Adults 18+ y
- Confirmed clinical diagnosis of mild-to-moderate asthma, defined as:
- A physician diagnosed asthma condition consistent with BTS/NICE/SIGN (2024)
- Asthma managed at GINA (2024) step 1-3 therapy level, with stable maintenance treatment for ≥4 weeks prior to enrolment
- No asthma exacerbation requiring systemic corticosteroids within the preceding 6-8 weeks
- (those with suspected Asthma will be invited to a familiarisation and eligibility session where they will have clinical investigations to assess for asthma and thus be included or excluded)
- Ability to demonstrate acceptable and repeatable spirometry in accordance with ATS/ERS standards
- Willing to refrain from antioxidant and anti-inflammatory supplementation (e.g. Omega-3, turmeric, NSAID supplements) for the duration of the study
- Not consuming high dietary ASTX sources (e.g., frequent salmonid or crustacean intake), assessed at screening
- non-smoking and non-vaping
- Able and willing to take daily study capsules and attend all required visits
- Able and willing to complete home monitoring, including peak flow, air-quality monitoring, and questionnaires
- Able to provide written informed consent
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Middlesex University Coordinator of this site? Confirm its status | London | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.